RecruitingPhase 1NCT07617727

A Phase I Study of JSKN021 in Advanced Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JSKN021 in Advanced Malignant Solid Tumors

Sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Enrollment

199 participants

Start Date

Jun 2, 2026

Study Type

INTERVENTIONAL

Conditions

Advanced malignant solid tumors

Summary

This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called JSKN021 for people with advanced malignant solid tumors. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGJSKN021

JSKN021 administered intravenously at selected dose levels according to protocol

Locations(6)

Tumor Hospital of Guangxi Medical University

Nanning, Guangxi, China

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China

Jiangsu Province Hospital

Nanjing, Jiangsu, China

Xuzhou Central Hospital

Xuzhou, Jiangsu, China

Affiliated Hospital of Jining Medical College

Jining, Shandong, China

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07617727

Related Trials

A Study of TPD3310 in Patients With Advanced Malignant Tumors

NCT073681271 location

N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

NCT076394506 locations

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

NCT074807331 location

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

NCT065732945 locations

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

NCT064993501 location